

Case study

Medable platform speeds diabetes study startup by 50%

Client overview

A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study in the highly competitive weight loss market. Their primary goal was to reduce the client's average study build timelines from 16-20 weeks, down to just 8 weeks, a reduction of more than 50%.

Client Challenge

The client faces intense competition in the highly-publicized weight loss market and wants to increase speed to market.

Medable's Solution

Medable and the client's teams analyzed existing startup processes, identified where technology and process refinement could create efficiencies, and created new core startup standards for the trial.

From there, the teams worked together to implement the capabilities of the Medable platform in screening, data collection, eCOAs, and more.

Additionally, Medable provided system integration, implementation, product configuration, change management, maintenance, and support as needed.

Key insights and outcomes

Medable's platform enabled the client to meet their goal of reducing study startup time to just 8 weeks. The entire study was built in a remarkable 8 weeks, from protocol finalization to go-live.

Enhanced efficiency and communication

Both sites and study teams reported increased efficiency and reduced back-and-forth communication, thanks to the streamlined processes and technology standards provided by Medable.

Competitive edge in the chronic weight management market

With accelerated timelines, the client gained a competitive edge in the highly competitive chronic weight management market. The client was able to continue the development and testing of their weight loss drug and respond to market demands quickly.

Reusable core processes

The Medable platform provided reusable core processes and technology standards, paving the way for faster study startup periods in future diabetes trials.

Conclusion:

Medable's patient-focused solution proved pivotal in the success of a top 10 pharma company's Phase III diabetes study launch.

The platform facilitated swift enrollment, reduced study startup time significantly, and enhanced communication and efficiency for both sites and study teams.

With Medable's support, the client achieved their goal of developing a weight loss drug and was better equipped to handle the competitive weight loss market. Moving forward, the client can rely on the reusable core processes and technology standards to expedite future diabetes trials.

